Table 2.
Fully published MAs and NMAs since 2016: PFS and OS in relapsed/refractory (R/R) patients [14,15,16,17,18,19].
| Author, Year | NMA | Sponsored | N Studies (Patients) | Intervention | Comparator | Hazard Ratio or Risk Ratio (Confidence or Credible Intervals) |
|---|---|---|---|---|---|---|
| PFS | ||||||
| Wu, 2017 [19] |
No | No | 13 (2314) |
Ofa-based | Non-Ofa-based | 0.88 (0.47–1.63) |
| Pula, 2018 [18] |
No | No | 5 (1866) |
BTK inhibitors | Non-BTK inhibitors | 0.24 (0.19–0.30) |
| Chen, 2019 [14] |
Yes | No | 7 (2514) |
RV I |
Ofa |
0.10
(0.05–0.21)
0.10 (0.07–0.17) |
| Lee, 2020 [15] |
No | Yes | 6 (1615) |
Lenalidomide (maint) R (maint) Ofa (maint) |
No maintenance |
0.37
(0.27–0.50)
0.50 (0.38–0.66) 0.52 (0.41–0.66) |
| Molica, 2019 [17] |
No | No | 7 (2409) |
I or A or V +/− R/O |
No BTK inhibitor nor venetoclax |
0.187 (0.126–0.279) non 17p- 0.240 (0.185–0.311) TP53wt 0.239 (0.166–0.344) IGVH mutated 0.208 (0.168–0.59) non 11q- 0.206 (0.108–0.392) 17p- 0.231 (0.137–0.390) TP53 mutated 0.172 (0.109–0.272) IGVH unmutated 0.081 (0.054–0.121) 11q- |
| OS | ||||||
| Wu, 2017 [19] |
No | No | 13 (2314) |
Ofa-based | Non-Ofa-based | 0.97 (0.70–1.36) |
| Pula, 2018 [18] |
No | No | 5 (1866) |
BCR-inhibitors | Non BCR-inhibitors | 0.58 (0.46–0.73) |
| Chen, 2019 [14] |
Yes | No | 7 (2514) |
RV I |
Ofa |
0.33
(0.11–0.99)
0.36 (0.21–0.63) |
| Molica, 2020 LL [16] |
Yes | No | 3 (1383) |
RV RB + I RB + idelalisib |
RB |
0.17
(0.11–0.25)
0.20 (0.15–0.28) 0.33 (0.25–0.44) |
| Lee, 2020 [15] |
No | Yes | 6 (1615) |
Lenalidomide, R, or Ofa maintenance | No maintenance | 0.89 (0.70–1.14) |
Bolded risk ratios show significantly increased (or reduced) hazards of adverse events of intervention versus comparator. Legend: A—acalabrutinib; BR—bendamustine plus rituximab; Chl—chlorambucil; F—fludarabine; FC—fludarabine and cyclo; A—acalabrutinib; BR—bendamustine plus rituximab; Chl—chlorambucil; F—fludarabine; FC—fludarabine and cyclophosphamide; FCR—fludarabine plus cyclophosphamide plus rituximab; FI—fludarabine ineligible; HG—grade 3–5; HR—hazard ratio; I—ibrutinib; IGVH—immunoglobulin heavy chain variable region; IR—ibrutinib plus rituximab; maint—maintenance; mut—mutated status; O—obinutuzumab; O-Chl—obinutuzumab plus chlorambucil; OA—obinutuzumab plus acalabrutinib; Ofa = ofatumumab; Ofa-Chl—ofatumumab plus chlorambucil; OI—obinutuzumab plus ibrutinib; OS—overall survival; OV—obinutuzumab plus venetoclax; PFS—progression-free survival; R—rituximab; R-Chl—chlorambucil plus rituximab; R/R—relapsed/refractory; RB—rituximab plus bendamustine; RV—rituximab plus venetoclax; V—venetoclax; unmut—unmutated status.